Abbott Laboratories (ABT.N) Quote| Reuters.com
Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

39.54USD
4:00pm EDT
Change (% chg)

$0.23 (+0.59%)
Prev Close
$39.31
Open
$39.31
Day's High
$39.71
Day's Low
$39.16
Volume
1,805,599
Avg. Vol
2,330,465
52-wk High
$51.72
52-wk Low
$36.00

ABT.N

Chart for ABT.N

About

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment... (more)

Overall

Beta: 1.01
Market Cap(Mil.): $57,752.37
Shares Outstanding(Mil.): 1,469.15
Dividend: 0.26
Yield (%): 2.65

Financials

  ABT.N Industry Sector
P/E (TTM): 27.67 35.27 36.15
EPS (TTM): 1.42 -- --
ROI: 6.57 15.09 14.31
ROE: 10.02 16.14 15.51

BRIEF-Abbott announces results from study of Freestyle Libre system for type 1 diabetes

* Abbott announces positive results from groundbreaking study of Freestyle Libre system for people with type 1 diabetes

Jun 13 2016

BRIEF-Abbott sets quarterly dividend of $0.26/shr

* Sets quarterly dividend of $0.26 per share Source text for Eikon: Further company coverage:

Jun 10 2016

BRIEF-Slate Retail REIT to acquire Abbott's village in Georgia

* Slate Retail REIT announces the purchase of Abbott's village in Georgia

May 16 2016

BRIEF-Alere obtains requisite lender approval for extension to file Form 10

* Announces certain developments relating to the pending merger transaction with abbott laboratories

Apr 28 2016

Abbott to buy St. Jude for $25 billion to boost heart devices

Abbott Laboratories said on Thursday that it would buy St. Jude Medical Inc in a $25 billion deal to expand its heart device business, but investors worried that the acquisition would not pay off as promised.

Apr 28 2016

LPC: Abbott’s $17.2 billion loan backing St. Jude acquisition set to boost M&A volume

NEW YORK A US$17.2bn bridge loan that backs Abbott Laboratories’ US$25bn acquisition of medical device maker St. Jude Medical will boost investment grade loan volume that so far this year has been depressed by volatility in equities and global economic uncertainty.

Apr 28 2016

Fitch Maintains Abbott on Rating Watch Negative

(The following statement was released by the rating agency) CHICAGO, April 28 (Fitch) Fitch Ratings has maintained Abbott Laboratories' (ABT, Abbott) 'A'/'F1' ratings on Rating Watch Negative. The rating action follows the announcement of Abbott's intention to acquire St. Jude Medical Inc. (STJ, St. Jude) and its previously announced agreement from February 2016 to acquire Alere Inc. (Alere). Fitch will resolve the Rating Watch as more details regarding the transactions become available. Ho

Apr 28 2016

UPDATE 1-LPC: Abbott's US$17.2bn loan backing St. Jude acq. set to boost M&A volume

NEW YORK, April 28 A US$17.2bn bridge loan that backs Abbott Laboratories' US$25bn acquisition of medical device maker St. Jude Medical will boost investment grade loan volume that so far this year has been depressed by volatility in equities and global economic uncertainty.

Apr 28 2016

LPC: Abbott's US$17.2bn loan backing St. Jude acq. set to boost M&A volume

NEW YORK, April 28 A US$17.2bn bridge loan that backs Abbott Laboratories' US$25bn acquisition of medical device maker St. Jude Medical will boost investment grade loan volume that so far this year has been depressed by volatility in equities and global economic uncertainty.

Apr 28 2016

BRIEF-S&P- Abbott Laboratories ratings remain on creditwatch negative on planned acquisition of St. Jude

* Abbott Laboratories ratings remain on creditwatch negative on planned acquisition of St. Jude Medical Source text: (http://bit.ly/21hkyCp) (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)

Apr 28 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $121.29 -0.01
Pfizer Inc. (PFE.N) $35.57 +0.36
Novartis AG (NOVN.S) CHF80.45 +0.30
Merck & Co., Inc. (MRK.N) $57.94 +0.33
Sanofi SA (SASY.PA) €75.02 +0.10
AstraZeneca plc (AZN.L) 4,502.50p +35.50
GlaxoSmithKline plc (GSK.L) 1,600.00p -4.50
Eli Lilly and Co (LLY.N) $78.95 +0.20
Amgen, Inc. (AMGN.OQ) $154.28 +2.13
Boston Scientific Corporation (BSX.N) $23.41 +0.04

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Validea
$12.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Wright Reports
$75.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.